Monitor IRulya's Phase 2 LAM-001 trial results for Bronchiolitis Obliterans Syndrome, expected Q1 2027, as warrant exercise and potential further accumulation by Perceptive hinge on this catalyst. The passive 13G filing signals institutional confidence but no near-term activism.
Price Chart
Executive Summary
Perceptive Advisors LLC disclosed a passive 8.4% stake in IRulya Therapeutics Inc. via a Schedule 13G filing, holding 912,853 shares of common stock through its Master Fund. The filing also notes warrants exercisable for additional shares contingent on Phase 2 trial results for Bronchiolitis Obliterans Syndrome, expected in Q1 2027. This is a new passive position by a notable healthcare-focused investment firm, indicating conviction in the company's pipeline.
Key Financial Metrics
Key Facts
- Perceptive Advisors LLC disclosed a 8.4% passive stake in IRulya Therapeutics Inc.
- Stake consists of 912,853 shares of common stock held by Perceptive Life Sciences Master Fund, Ltd.
- Warrants exercisable for additional shares are contingent on Phase 2 trial results for Bronchiolitis Obliterans Syndrome (LAM-001), expected Q1 2027.
- Filing is a new position (not an amendment) and certifies passive intent under Rule 13d-1(c).
- Perceptive Advisors is a healthcare-focused investment firm; Joseph Edelman is the managing member.
Financial Impact
8.4% stake valued at approximately $[undisclosed] based on current market price; warrants provide potential for additional upside contingent on trial results.
Risk Factors
- Phase 2 trial failure could lead to stock decline and warrant expiration worthless.
- Passive filing means Perceptive cannot influence management; no activist catalyst.
- Warrant exercise is time-limited and contingent on trial results, creating binary risk.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0001193125-26-421651 |
| Document: 0001193125-26-421651-index.html | 0001193125-26-421651 |
| Document: 0001193125-26-421651.txt | 0001193125-26-421651 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 144 | $32.83 | awaiting T+20 | — | $31.38 (−4.42%) |
Oct 19, 2026 8d ago | 3 | $40.27 | awaiting T+20 | — | $31.38 (−22.08%) |
Oct 19, 2026 8d ago | 3 | $40.27 | awaiting T+20 | — | $31.38 (−22.08%) |
Oct 19, 2026 8d ago | 3 | $40.27 | awaiting T+20 | — | $31.38 (−22.08%) |
Oct 19, 2026 8d ago | 3 | $40.27 | awaiting T+20 | — | $31.38 (−22.08%) |
Oct 19, 2026 8d ago | 3 | $40.27 | awaiting T+20 | — | $31.38 (−22.08%) |
Oct 19, 2026 8d ago | 8-K | $34.45 | awaiting T+20 | — | $31.38 (−8.91%) |
Oct 14, 2026 13d ago | SC 13G | $33.23 | awaiting T+20 | — | $31.38 (−5.57%) |
Oct 14, 2026 13d ago | SC 13G | $33.23 | awaiting T+20 | — | $31.38 (−5.57%) |
Oct 6, 2026 21d ago | 8-K | $26.72 | awaiting T+20 | — | $31.38 (+17.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers